Please note, this conference is being recorded. I will now turn the conference over to Cory Edwards, Vice President of Corporate Communications. Thank you. You may begin. Good afternoon. On the call ...

Q1 2026 earnings call recap: data center-driven growth, Eco-Pan strength, updated guidance, CapEx plans & risks—read now.

Q4 2025 earnings call recap: record test volume, ASP trends, 2026 revenue guidance ($70–$73M) and path to profitability.

Q4 2025 earnings call: 2026 revenue guidance, COVID vaccine outlook, oncology pipeline updates, and leadership transition—read now.

This series has been designed to highlight the company's exploration and development strategy with a specific focus on our growing Vietnam business. Today's webinar will feature prepared remarks by ...

Founder, Director & CEO, reported record-breaking fourth quarter and full year 2025 results, attributing success to “continued new customer volume additions, successful scale-up of our integrated ...

Permian strength, rising dividend, buybacks and 2026 growth outlook. Click here to read my most recent analysis of VNOM.

The Global X Uranium ETF (URA) is one of the best tools to be constructive on uranium miners, developers, and nuclear tech amid a secular energy transition. Read the full analysis here.

Jeffrey MacLauchlan Executive VP, CFO, & Treasurer. Sure. So an important part of our strategy over the last decade or so has been to deliberately position ourselves in areas of t ...

The Middle East conflict hasn’t spiked oil yet—see why prices stay moderate, shale can’t quickly fill gaps, and recession risks grow. Read my analysis here.

CEO Kenneth Romanzi highlighted that "Nature's Sunshine delivered another terrific quarter, growing sales 5% and EBITDA at 10% and by continuing to execute against its key drivers of success, leading ...

GH Research PLC is rated a Buy with $280.7M in cash, supporting lead candidate GH001 for Treatment-Resistant Depression. Read more on GHRS stock here.